Two Sigma Securities’s Aclaris Therapeutics ACRS Stock Holding History

Two Sigma Securities’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67K	Sell	12,671 -9,800	-44%	-$43.7K	0.01%	1352
2026 Q1	$84.3K	Buy	22,471 +10,926	+95%	+$36.9K	0.01%	1199
2025 Q4	$34.8K	Buy	11,545 +959	+9%	+$2.42K	﹤0.01%	1114
2025 Q3	$20.1K	Buy	+10,586	New	+$18.5K	﹤0.01%	1139
2024 Q4	–	Sell	-10,740	Closed	-$12.4K	–	1575
2024 Q3	$12.4K	Buy	+10,740	New	+$13.2K	﹤0.01%	2562
2024 Q2	–	Sell	-16,114	Closed	-$20K	–	2926
2024 Q1	$20K	Buy	+16,114	New	+$19.2K	﹤0.01%	2676

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Two Sigma Securities's ACRS Position: Q2 2026 in Review

Two Sigma Securities reduced its Aclaris Therapeutics (ACRS) stake by 44% in Q2 2026, selling an estimated $43.7K and leaving 12,671 shares worth $67K. The position accounts for 0.01% of the portfolio, ranked #1352.

Two Sigma Securities first reported a position in ACRS in Q1 2024 and has held it in 6 quarters since. The position peaked at $84.3K in Q1 2026. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Two Sigma Securities held 12,671 shares of Aclaris Therapeutics worth $67K as of Q2 2026.
Two Sigma Securities sold 9,800 Aclaris Therapeutics shares in Q2 2026, an estimated $43.7K.
Aclaris Therapeutics made up 0.01% of Two Sigma Securities's portfolio in Q2 2026, its #1352 holding.
Two Sigma Securities first reported a position in Aclaris Therapeutics in Q1 2024 and has held it in 6 quarters since.
Two Sigma Securities's Aclaris Therapeutics position peaked at $84.3K in Q1 2026.
148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.